- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03997864
Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault
Administration of Prazosin to Prevent PTSD After Sexual Assault
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study plans to learn more about whether taking the medication, Prazosin, in the weeks immediately following a traumatic event can help to reduce the risk of developing posttraumatic stress disorder (PTSD).
Specific Aim 1: Test the efficacy of the drug prazosin in decreasing PTSD symptom severity as compared to placebo at 3 months post rape as measured by the Clinician-Administered PTSD Scale version 5 (CAPS-5, primary outcome) as well as associated secondary outcomes (PTSD diagnosis rate, sleep scores, and depression symptoms) at 3 months.
Hypotheses:
1a: Severity score on the CAPS-5 will be significantly lower in rape victims randomized to receive prazosin within 24 hours of at the University of Colorado Hospital (UCH) Emergency Department and continue on a titrated dose for one month compared to the control group at 3 months post rape. Secondarily, PTSD diagnosis rate will be lower in the prazosin group versus the control group at 3 months.
1b: Participants randomized to receive prazosin will have better sleep scores as measured by the Pittsburgh Sleep Quality Index (PSQI) and PSQI Trauma addendum at 3 months post rape as compared to the control group.
1c: Severity scores for major depressive symptoms as measured by the Patient Health Questionnaire (PHQ-9) will be significantly lower in rape victims randomized to receive prazosin as compared to the control group at 3 months post rape.
1d: Sleep scores as measured by the PSQI and PSQI Trauma addendum will be positively correlated with PTSD symptom severity as measured by the CAPS-5 such that higher (worse) sleep scores are associated with more PTSD symptoms.
Rationale: Many studies have shown that sleep disturbances and nightmares that occur directly after a traumatic event are a good predictor of the development of PTSD. Prazosin has been shown to improve PTSD-related sleep disturbance, including nightmares. If prazosin can effectively treat sleep disturbance in the weeks immediately following a traumatic experience and decrease the rate of PTSD and the severity of symptoms, then it could possibly become the standard of care for individuals exposed to a traumatizing event.
Brief overview of methods: Females between the ages of 18 and 50 years will be recruited directly from the ED at University of Colorado Hospital with the assistance of the Forensic Nurse Examiners. Those who elect to take part in this study and complete the informed consent process will be randomized to receive either prazosin or placebo. This is a double-blind study, so neither the participant nor the study doctor/team will know whether a participant is in the treatment (prazosin) or control (placebo) group. Participants will receive three 2mg tabs and three 1mg tbs for titration purposes (prazosin or placebo equivalent) before they leave the hospital, with instructions to take the first dose (2 mg) 1 hour before bed, the first night after being seen in the ED. Study staff will follow up the next day to inquire about the participant's general condition, possible side-effects, sleep, and to schedule the first study visit (at ~72 hours after treatment in ED). PTSD and posttraumatic stress symptoms, symptoms of depression, suicidality, medication compliance, side-effects and adverse events will be monitored and assessed by study personnel at weekly study visits for the duration of the med trial (~6 weeks; 3 weeks on medication and 2-3 weeks of tapering off of medication) and again at 3-months post. However, participants will be instructed to report any changes or concerns as needed. Each participant will also complete a daily sleep log for the duration of their participation in the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Steven J Berkowitz, MD
- Phone Number: (303)724-7306
- Email: steven.berkowitz@cuanschutz.edu
Study Contact Backup
- Name: Amanda M Millar, MSS
- Phone Number: 2672308265
- Email: amanda.millar@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado
-
Contact:
- Amanda M Millar, MSS
- Phone Number: 267-230-8265
- Email: amanda.millar@cuanschutz.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients between the ages of 18 years and 50 years
- Victim of sexual assault/rape
- Able to understand consent procedure
- Discharged to home
Exclusion Criteria:
- Admitted to inpatient unit
- Previous diagnosis of PTSD
- Contra-indications to prazosin: orthostatic hypotension, right heart failure, use of anti-hypertensive medication, 5-phosphodiesterase inhibitors (sildenafil) or diuretic, history of syncope or severe unexplained faintness, known hypersensitivity to quinazolines
- Hemodynamically unstable
- Current use of over the counter, prescribed, or use of other drugs for insomnia
- Dependence on alcohol, opiates or other illegal drugs
- History of psychotic disorder
- Suicidal risk defined by a positive response on the 3-item assessment, standard protocol in the ED
- Current use of morphine or methadone
- Pregnant or breastfeeding
- Known hepatic dysfunction
- Cardiac or vascular history including coronary artery disease
- Narcolepsy
- History of sleep apnea
- Returning to chronic domestic abuse situation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment - prazosin
Participants randomized to this group will receive the medication prazosin.
|
Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic. Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks.
Other Names:
|
Placebo Comparator: Control - placebo
Participants randomized to this group will receive placebo .
|
Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PTSD symptoms and severity - Clinician-Administered PTSD Scale - 5 (CAPS-5)
Time Frame: The full interview takes 45-60 minutes to administer and will be given at baseline, at approximately 31 days post event, and at three months.
|
Clinician-Administered PTSD Scale-5 (CAPS-5) - Past Month & Past Week.
The CAPS is the gold standard in PTSD assessment and the total score will serve as the primary outcome.
The CAPS-5 is a 30-item structured interview to make a current (past month) diagnosis of PTSD, a lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week.
The full interview takes 45-60 minutes to administer and will be given at baseline, at approximately 31 days post event, and at three months.
|
The full interview takes 45-60 minutes to administer and will be given at baseline, at approximately 31 days post event, and at three months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: The PSQI will be completed weekly through study completion (average three months).
|
The PSQI is a 19-item self-report questionnaire that assesses sleep quality over a 1-month interval.
The questionnaire takes 10-15 minutes to complete.
Total score from PSQI will be a secondary outcome of sleep with higher score indicating poorer sleep quality.
|
The PSQI will be completed weekly through study completion (average three months).
|
Pittsburgh Sleep Quality Index - Trauma Addendum (PSQI-A)
Time Frame: The PSQI-A will be completed weekly through study completion (average three months).
|
The PSQI-A is a 7-item self-report questionnaire administered in conjunction with PSQI to examine the frequency of seven disruptive nocturnal behaviors common to PTSD among adults.
Total score on PSQI-A will be a secondary outcome of trauma-associated sleep issues.
|
The PSQI-A will be completed weekly through study completion (average three months).
|
Patient Health Questionnaire (PHQ-9)
Time Frame: It takes about five minutes to complete and will be assessed weekly for the first seven weeks of participation and at three months/study completion (at each study visit).
|
The PHQ-9 is a 10-item self-report questionnaire used in screening, diagnosing, monitoring, and measuring the severity of depression.
Using an independent structured mental health professional interview as the criterion standard, a PHQ-9 score of 10 or more corresponded to good sensitivity and specificity (both 88%) for major depression.33
Total score will be a secondary outcome of depression symptom severity and score >=10 will be used to indicate major depression at 3 months.
|
It takes about five minutes to complete and will be assessed weekly for the first seven weeks of participation and at three months/study completion (at each study visit).
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Trauma and Stressor Related Disorders
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Prazosin
Other Study ID Numbers
- 19-0733
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Posttraumatic Stress Disorder
-
University Hospital, ToursCompletedPostTraumatic Stress DisorderFrance
-
The University of Texas Health Science Center at...University of Pennsylvania; Brooke Army Medical Center; C.R.Darnall Army Medical... and other collaboratorsCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Icahn School of Medicine at Mount SinaiCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Berlin Center for the Treatment of Torture VictimsCompletedPosttraumatic Stress Disorder (PTSD)Germany
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Michael E. DeBakey VA Medical CenterSouth Central VA Mental Illness Research, Education & Clinical CenterCompletedPosttraumatic Stress Disorder (PTSD)United States
-
TEMPVA Research Group, Inc.C.R.Darnall Army Medical Center; VA Boston Healthcare System; Central Texas Veterans...UnknownPosttraumatic Stress Disorder, Combat-relatedUnited States
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompleted
-
Yale UniversityNational Center for PTSDCompletedPosttraumatic Stress Disorder (PTSD)United States
Clinical Trials on Prazosin
-
Seattle Institute for Biomedical and Clinical ResearchNational Institute on Alcohol Abuse and Alcoholism (NIAAA); United States Department... and other collaboratorsCompletedStress Disorders, Post-Traumatic | Sleep Disorders | Combat DisordersUnited States
-
PfizerCompletedHeart Failure | HypertensionUnited States
-
Centre for Addiction and Mental HealthPfizer; Ontario Lung AssociationCompleted
-
Seattle Institute for Biomedical and Clinical ResearchUnited States Department of Defense; VA Puget Sound Health Care SystemCompletedAlcohol Use Disorders | Combat Disorders | Stress Disorders, PosttraumaticUnited States
-
Haffkine Bio-Pharmaceutical Corporation Ltd.Completed
-
Rainier AssociatesUnknownStress Disorders, Post-TraumaticUnited States
-
VA Office of Research and DevelopmentCompletedPTSD | Sleep DisordersUnited States
-
Sohag UniversityRecruiting
-
University of British ColumbiaCompletedAutonomic DysreflexiaCanada
-
VA Puget Sound Health Care SystemUniversity of Washington; VA Mental Illness Research, Education and Clinical...RecruitingCannabis Dependence | Posttraumatic Stress Disorder | Cannabis Use DisorderUnited States